Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 6
Submit an article Journal homepage
39
Views
4
CrossRef citations to date
0
Altmetric
Review

Novel therapeutics in adult malignant brain gliomas

Michele Reni
,
Elena Mazza Department of Oncology, San Raffaele H. Scientific Institute via Olgettina 60, 20132 Milan. [email protected]
,
Alicia Tosoni Department of Oncology, Neuroncology Unit, University Hospital, Padua, Italy
&
Alba A Brandes Department of Oncology, Neuroncology Unit, University Hospital, Padua, Italy
Pages 643-658 | Published online: 11 Jul 2005

Bibliography

  • FINE HA, DEAR KB, LOEFFLER JS, BLACK P, CANNELLOS GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 71:2585–2597.
  • STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet (2002) 359:1011–1018.
  • THOMAS D, BRADA M, STENNING S et al: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. I. Gin Oncol (2001) 19:509–518.
  • STUPP R, MASON W, VAN DEN BENT M et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl. J. Med. (2005) 352: 987–996.
  • •An abstract describing the first step forward after more than two decades in the standard treatment of glioblastoma.
  • WONG ET, HESS KR, GLEASON MJ et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Gin Oncol (1999) 17:2572–2578.
  • MISCHEL PS, CLOUGHESY TF: Targeted molecular therapy of GBM. Brain Pathol (2003) 13:52–61.
  • ••A thorough review of the rationale fortargeted molecular therapy.
  • RAO RD, JAMES D: Altered molecular pathways in gliomas: an overview of clinically relevant issues. Senna Oncol (2004) 31:595–604.
  • ••A thorough review of the rationale fortargeted molecular therapy.
  • TREMONT-LUKATS IW, GILBERT MR: Advances in molecular therapies in patients with brain tumors. Cancer Control (2003) 10:125–137.
  • ••A comprehensive review of the rationalefor targeted molecular therapy.
  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57–70.
  • HOLLAND EC: Gliomagenesis: genetic alterations and mouse models. Nat. Rev Cancer (2001) 2:120–129.
  • MAHER EA, FUNARI FB, BACHOO RM et al: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15:1311–1333.
  • JENDROSSEK V, BELKA C, BAMBERG M: Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opia Investig. Drugs (2003) 12:1899–1024.
  • SLICHENMYER WJ, ROWINSKY EK, GROCHOW LB, KAUFMANN SH, DONEHOWER RC: Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother. Pharmacol (1994) 34:S53-S57 (Suppl.).
  • HARE CB, ELI ON GB, HOUGHTON PJ et al.: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl- 0-(4- [1-piperidino] -1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. (1997) 39:187–191.
  • HOUGHTON PJ, CHESHIRE PJ, HALLMAN JD II et al.: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. (1995) 36:393–403.
  • GILBERT MR, SUPKO JG, BATCHELOR T et al.: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. (2003) 9:2940–2949.
  • PRADOS MD, YUNG WK, JAECKLE KA et al.: Phase I trial of irinotecan (CPT-1 1) in patients with recurrent malignant glioma: a North American brain tumor consortium study. Neuro-oncol (2004) 6:44–54.
  • FRIEDMAN HS, PETROS WP FRIEDMAN AH et al.: Irinotecan therapy in adults with recurrent or progressive malignant glioma.Oncol. (1999)17:1516–1525.
  • PARKER RJ, FRUEHAUF JP, MEHTA R, FILKA E, CLOUGHESY T: A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. Neurooncol. (2004) 66:365–375.
  • RAYMOND E, FABBRO M, BOIGE V et al.: Multicentre Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol. (2003) 14:603–614.
  • CLOUGHESY TF, FILKA E, KUHN J et al.: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer (2003) 97\(Suppl. 9):2381–2386.
  • BATCHELOR TT, GILBERT MR, SUPKO JG et al: Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-oncol (2004) 6:21–27.
  • REARDON DA, QUINN JA, VREDENBURGH J et al.: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer (2005) 103:329–338.
  • DESJARDINS A, REARDON D, VREDENBURG J et al.: Phase I trial of adults with primary malignant glioma with irinotecan (CPT-1 1) plus temozolomide (TEMODAR). Neuro-Oncol (2004) 6:373–374.
  • GRUBER ML, BUSTER WP: Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. I Clin. Oncol. (2004) 27:33–38.
  • BRANDES AA, TOSONI A, BASSO U et al.: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italian° Cooperativo di Neuro-Oncologia (GICNO). j Clin. Oncol. (2004) 22:4727–4734.
  • SUNG C, BLANEY SM, COLE DE et al:A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. (1994) 54:5118–5122.
  • LESIMPLE T, HASSEL MB, GEDOUIN D et al.: Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma. Neurooncol. (2003) 65:141–148.
  • FISHER B, WON M, MacDONALD D et al.: Phase II study of topotecan plus cranial radiation for Glioblastoma multiforme: results of radiation therapy Oncology group 9513. Int. J. Radiat. Oncol. Biol. Phys. (2002) 53:980–986.
  • DE CESARE M, PRATESI G, PEREGO P et al.: Potent antitumor activity and improved pharmacological profile of 5T1481, a novel 7-substituted camptothecin. Cancer Res. (2001) 61:7189–7195.
  • PRATESI G, BERETTA GL, ZUNINO F et al.: Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs (2004) 15:545–552.
  • LEE G, DALLAS S, HONG M, BENDAYAN R: Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev (2001) 53:569–596.
  • DE CESARE M, PRATESI G, VENERONI S, BERGOTTINI R, ZUNINO F: Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin. Cancer Res. (2004) 10:7357–7364.
  • SUPKO G, ALDERSON L, WEN P et al.:Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas. Proc. Am. Soc. Clin. Oncol. (2004) 23:2039 (Abstarct).
  • MANFREDI JJ, PARNESS J, HORWITZ SB: Taxol binds to cellular microtubules. J. Cell Biol. (1982) 94:688–696.
  • GEARD CR, JONES JM, SCHIFF PB: Taxol and radiation. Monogr. Nat. Cancer Inst. (1993) 15:89–94.
  • FOUNTZILAS G, KARAVELIS A, CAPIZZELLO A et al.: Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A Phase II study. I Neurooncol. (1999) 45:159–165.
  • JULKA PK, AWASTHY BS, RATH GK et al: A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. Australas. Radio]. (2000) 44:84–87.
  • SCHUCK A, MULLER SB, KOHLER A et al.: Combined radiochemotherapy with paclitaxel in the treatment of malignant glioma. Strahlenther. Onkol. (2002) 178:486–490.
  • MARTIN C, BERRIDGE G, HIGGINS CF, MISTRYP, CHARLTON P, CALLAGHAN R: Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. (2000) 58:624–632.
  • CHANG SM, KUHN JG, RIZZO J et al:Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. Clin. Oncol. (1998) 16:2188–2194.
  • KOUKOURAKIS MI, GIATROMANOLAKI A, SCHIZA S, KAKOLYRIS S, GEORGOULIAS V: Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int. J. Radiat. Oncol. Biol. Phys. (1999) 43:107–114.
  • SANSON M, NAPOLITANO M, YAYA R et al: Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a Phase II study. Neuro-oncol (2000) 50:245–249.
  • DIETZMANN A, KANAKIS D, KIRCHES E, KROPF S, MAWRIN C, DIETZMANN K: Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton. Neurooncol. (2003) 65:99–106.
  • PEEREBOOM D, CARSON K, LAWSON D, LESSER G, SUPKO J, GROSSMAN S: A Phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas. Proc. Am. Soc. Clin. Oncol. (2004) 23:1546 (Abstract).
  • ISHIKAWA T, SEKIGUCHI F, FUKASE Y, SAWADA N, ISHITSUKA H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. (1998) 58:685–690.
  • SCHULLER J, CASSIDY J, DUMONT Pet al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. (2000) 45:291–297.
  • NISHIMURA G, TERADA I, KOBAYASHI T: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol. Rep. (2002) 9:479–482.
  • BLANQUICETT C, GILLESPIE GY, NABORS LB et al: Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol. Cancer Ther. (2002) 1:1139–1145.
  • NEWMAN AJ, FIVEASH J, ROSENFELD S et al.: A Phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) 23:1537 (Abstract).
  • WOLFF JE, TRILLING T, MOLENKAMP G, EGELER RM, JURGENS H: Chemosensitivity of glioma cells in vitro: a meta analysis. J. Cancer Res. Clin. Oncol. (1999) 125:481–486.
  • CABANES A, TZEMACH D, GOREN D, HOROWITZ AT, GABIZON A: Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res. (1998) 4:499–505.
  • VAAGE J, BARBERA-GUILLEM E, ABRA R, HUANG A, WORKING P: Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer (1994) 73:1478–1484.
  • FABEL K, DIETRICH J, HAU P et al: Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer (2001) 92:1936–1942.
  • HAU P, FABEL K, BAUMGART U et al:Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer (2004) 100:1199–1207.
  • BIGNER SH, HUMPHREY PA, WONG AJ et al.: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. (1990) 50:8017–8022.
  • HUMPHREY PA, WONG AJ, VOGELSTEIN B et al: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. (1988) 48:2231–2238.
  • AGOSTI RIVI, LEUTHOLD M, GULLICK WJ et al.: Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch. A. Pathol. Anat. Histopathol. (1992) 420:321–325.
  • LIBERMAN TA, RAZON N, BARTAL AD et al.: Expression of EGF receptor in human brain tumors. Cancer Res. (1984) 44:753–760.
  • SUGAWA N, YAMAMOTO K, UEDA S et al: Function of aberrant EGFR in malignant gliomas. Bran] Tumor Pathol. (1998) 15:53–57.
  • BASELGA J: New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal (2001) 1:1–21.
  • CHAKRAVARTI A, DICKER A, MEHTA M: The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int. I Radiat. Oncol. Biol. Phys. (2004) 58:927–931.
  • BARKER FG, II, SIMMONS ML, CHANG SM et al: EGFR overexpression and radiation response in glioblastoma multiforme. Int. I Radiat. Oncol. Biol. Phys. (2001) 51:410–418.
  • OCHS JS: Rationale and clinical basis for combining gefitinib (iressa, ZD-1839) with radiation therapy for solid tumors. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58:941–949.
  • •A detailed review of the rationale for combining EGFR inhibitors with radiotherapy.
  • RICH JN, REARDON DA, PEERY T et al: Phase II trial of gefitinib in recurrent glioblastoma. ./. Clin. Oncol. (2004) 22:133–142.
  • SWAISLAND H, SMITH RP, FAREBROTHER J et al: The effects of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral doses of ZD1839 (Iressi), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in healthy male volunteers. Proc. Am. Soc. Clin. Oncol. (2002) 21:328 (Abstract).
  • CLARK GM, PEREZ-SOLER R, SIU L et al: Rash severity is predictive of increased survival with erlotinib HCL. Proc. Am. Soc. Oncol. (2003) 22:786 (Abstract).
  • SALTZ L, KIES M, ABBRUZZESE JL et al.: The presence and intensity of the cetuximab-induced acne-like rah predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. OM. Oncol. (2003) 22:817 (Abstract).
  • LIEBERMAN FS, CLOUGHESY T, FINE H et al: NABTC Phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc. Am. Soc. Clin. Oncol. (2004) 23:1510 (Abstract).
  • LEARN CA, HARTZELL TL, WILKSTRAND CJ et al.: Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin. Cancer Res. (2004) 10:3216–3224.
  • UHM JH, BALLMAN KV, GIANNINI C et al.: Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. Proc. Am. Soc. Clin. Oncol. (2004) 23:1505 (Abstract).
  • PRADOS M, YUNG W, WEN P et al: Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proc. Am. Soc. Oncol. (2004) 23:1504 (Abstract).
  • CHAKRAVARTI A, SEIFERHELD W, ROBINS HI et al: An update of Phase I data from RTOG 0211: A Phase I/II clinical study of gefitinib + radiation for newly-diagnosed glioblastoma (GBM) patients. Proc. Am. Soc. Clin. Oncol. (2004) 23:1571 (Abstract).
  • RAIZER JJ, ABREY LE, WEN P et al: A Phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc. Am. Soc. Clin. Oncol. (2004) 23:1502 (Abstract).
  • YUNG A, VREDENBURGH J, CLOUGHESY T et al.: Erlotinib HCL for glioblastoma multiforme in first relapse, a Phase II trial. Proc. Am. Soc. Chi'. Oncol. (2004) 23:1555 (Abstract).
  • VOGELBAUM MA, PEEREBOOM D, STEVENS GHJ et al.: Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a Phase II study. Neuro-Oncology (2004) 6:384 (Abstract TA–59).
  • PRADOS M, CHANG S, BURTON E et al: Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Chi'. Oncol. (2003) 22:394 (Abstract).
  • PEEREBOOM DM, BREWER C, STEVENS GHJ et al.: Phase II trial of erlotinib with temozolomide and concurrent radiation therapy post-operatively in patients with newly diagnosed glioblastoma multiforme. Neuro-Oncol (2004) 6:379 (Abstract TA–41).
  • PAEZ JM, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497–1500.
  • LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl. J. Med. (2004) 350:2129–2139.
  • PAO W, MILLER V, ZAKOVSKI M et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306–13311.
  • MURTHY U, BASU A, RODECK U et al.: Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch. Biochem. Biophys. (1987) 252:549–560.
  • STRAGLIOTTO G, VEGA F, STASIECKI P et al.: Multiple infusion of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD-55900) in patients with recurrent malignant giomas. Eur. J. Cancer (1996) 32A:636–640.
  • ROSZMAN T, ELLIOTT L, BROOKS W: Modulation of T-cell function by gliomas. Immunol. Today(1991) 12:184–193.
  • KUPPNER MC, HAMOU ME SAWAMURA Y et al: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor 02. J.Neurosurg. (1989) 71:211–217.
  • EMRICH JG, BRADY LW, QUANG TS et al.: Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. J. Clin. Oncol. (2002) 25:541–546.
  • RAYMOND E, BRANDES A, VAN OOSTEROM A et al: Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG intergroup study. Proc. Am. Soc. Clin. Oncol. (2004) 23:501 (Abstract).
  • WEN PY, YUNG WKA, LAMBORN K et al.: Phase I/II study of imatinib mesylate (STI-571) for patients with recurrent malignant glioma (NABTC 99–08). Neuro-Oncology (2004) 6:385 (Abstract TA–63).
  • DRESEMANN G: Imatinib (STI-571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients. Proc. Am. Soc. Oncol. (2004) 23:1550 (Abstract).
  • REARDON D, FRIEDMAN A, HERNDON J et al: Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. Neuro-Oncology (2004) 6:381 (Abstract TA–47).
  • KLEIHUES P, OHGAKI H: Primary andsecondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology (1999) 1:44–51.
  • LIU W, JAMES CD, FREDERICK L et al:PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. (1997) 57:5254–5257.
  • TOHMA Y, GRATAS C, BIERNAT W et al.: PTEN (IVIMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Neuropathol. Exp. Neurol. (1998) 57:684–689.
  • VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat. Rev Cancer (2002) 2:489–501.
  • SMITH JS, TACHIBAN I, PASSE SM et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Nat. Cancer Inst. (2001) 93:1246–1256.
  • SASAKI H, ZLATESCU MC, BETENSKY RA et al.: PTEN is a target of chromosome 10q loss in AODs and PTEN alterations are associated with poor prognosis. Am. J. Patna (2001) 159:359–367.
  • CHANG SM, KUHN J, WEN P et al.: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs (2004) 22:427–435.
  • GALANIS E, BUCKNER JC, MAURER M et al: NCCTG Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) 23:1503 (Abstract).
  • BUCKNER JC, PRADOS M, ROWINSKY EK et al.: A Phase I study of the safety, tolerability, and pharmacokinetics of intravenous CCI-779 given once daily for 5 days every two weeks to patients with CNS tumors. Neuro-Oncology (2002) 4:365.
  • ESHLEMAN JS, CARLSON BL, MLADEK AC et al: Inhibition of the mammalian target of rapamycin sensitizes U87 xenograft to fractionated radiation therapy. Cancer Res. (2002) 62:7291–7297.
  • REBOLLO A, MARTINEZ A: Ras proteins: recent advances and new functions. Blood (1999) 94:2971–2980.
  • KUHN JG, PRADOS M, ROBINS HI et al: Phase I trial of R115777 (Zarnestra) in patients with recurrent malignant glioma taking enzyme inducting antiepileptic drugs (EIAED). A North American Brain Tumor Consortium (NABTC) Report. Proc. Am. Soc. Clin. Oncol. (2002) 21:342 (Abstract).
  • CLOUGHESY TF, KUHN J, WEN P et al: Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED). A North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. (2002) 21:317 (Abstract).
  • GILBERT MR, HESS K, GAUPP P et al: A Phase I study of temozolomide and the farnesyltransferase inhibitor, tipifarnib in recurrent glioblastoma: a dose and schedule intensive regimen. Neuro-Oncology (2004) 6:375 (Abstract TA–23).
  • DELMAS C, HELIEZ C, COHEN-JONATHAN E et al: Farnesyltransferase inhibitor R-115777 reverses the resistance of human glioma cell line to ionizing radiation. Int. J. Cancer (2002) 100:43–48.
  • FOLKMAN J: Tumor angiogenesis: therapeutic implications. N Engl. I Med. (1971) 285:1182–1186.
  • ••A seminal paper describing the understanding of current targeted therapy.
  • BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev Cancer (2003) 3:401–410.
  • DVORAK HF: How tumors make bad blood vessels and stroma. Am. J. Pathol. (2003) 162:1747–1757.
  • FERRARA N, GEBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669–676.
  • STRATMAN A, MACHEIN MR, PLATE KH: Anti-angiogenic gene therapy of malignant glioma. Acta Neurochir (Wien) (1997) 68:105–110.
  • WESSELING P, RUITER DJ, BURGER PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. Neurooncol (1997) 32:253–265.
  • CONRAD C, FRIEDMAN H, REARDON D et al: A Phase I/II trial of single-agent PTK-787/ZK 222584 (PTK/ ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol (2004) 23:1512 (Abstract).
  • REARDON D, FRIEDMAN H, YUNG WKA et al: A Phase I/II trial of PTK787/ZK-222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM) Proc. Am. Soc. Clin. Oncol (2004) 23:1513 (Abstract).
  • HESS C, VUONG V, HEGYL I et al: Effect of VEGF receptor inhibitor PTK787/ ZK-222584 combined with ionizing radiation on endothelial cells and tumor growth. Br. J. Cancer (2001) 85:2010–2016.
  • FINE HA, KIM L, ROYCE C et al.: A Phase II trial of LY-317615 in patients with recurrent high grade gliomas. Proc. Am. Soc. Clin. Oncol (2004) 23:1511 (Abstract).
  • D'AMATO RJ, LOUGHNAN MS, FLYNN E et al.: Thalidomide is an inhibitor of angiogenesis. Proc. Nat. Acad. Sci. USA (1994) 91:4082–4085.
  • FINE HA, FIGG WD, JAECKLE K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high- grade gliomas.Oncol (2000)18:708–715.
  • MARX GM, PAVLAKIS N, McCOWATT S et al: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. .1 Neurooncol. (2001) 54:31–38.
  • SHORT SC, TRAISH D, DOWE A ad.: Thalidomide as an anti-angiogenic agent in relapsed gliomas. Neurooncol (2001) 51:41–45.
  • MORABITO A, FANELLI M, CARILLIO G et al: Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep. (2004) 11:93–95.
  • FINE HA, WEN PY, MAHER EA et al: Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. Clin. Oncol (2003) 21:2299–2304.
  • CHANG SM, LAMBORN KR, MALEC M et al.: Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. (2004) 60:353–357.
  • DESJARDINS A, QUINN J, REARDON D et al: Phase II study of thalidomide and daily low-dose cyclophosphamide for adults with anaplastic gliomas. Neuro-Oncology (2004) 6:373 (Abstract TA–16).
  • WEN PY, GIGAS DC, MacDONALD L et al: Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma. Neuro-Oncology (2004) 6:385 (Abstract TA–64).
  • NABORS LB, ROSENFELD SS, MIKKELSEN T et al.: NABTT 9911: a Phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Neuro-Oncology (2004) 6:379 (Abstract TA–39).
  • HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinases inhibitors in cancer therapy. J. Nat. Cancer Inst. (2001) 93:178–193.
  • FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat. Med. (1995) 1:27–31.
  • JAALINOJA J, HERVA R, KORPELA M et al: Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. Neurooncol (2000) 46:81–90.
  • LARSON DA, PRADOS M, LAMBORN KR et al: Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int. J. Radiat. Oncol Biol. Phys. (2002) 54:1397–1404.
  • GROVES MD, PUDUVALLI VK, HESS KR et al.: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. ./. Clin. Oncol (2002) 20:1383–1388.
  • YUNG A, ALBRIGHT R, OLSON J et al: A Phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. BE J. Cancer (2000) 83:588–593.
  • BRADA M, HOANG-XUAN K, RAMPLING R et al: Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol (2001) 12:259–266.
  • BRANDES AA, PASETTO LM, VASTOLA F et al: Temozolomide in patients with high-grade gliomas. Oncology (2000) 59:181–186.
  • PHUPHANIC S, LEVIN V, YUNG W et al.: A multicenter, randomized, double blind, placebo-controlled trial of marimastat in patients with glioblastoma multiforme or gliosarcoma following completion of conventional first-line treatment. Proc. Am. Soc. Clin. Oncol (2001) 20:205 (Abstract).
  • •A report of the first Phase III trial of targeted therapy in high-grade gliomas.
  • SPARANO JA, BERNARDO P, STEPHENSON P et al.: Randomized Phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first line chemotherapy: Eastern cooperative Oncology Group trial E2196.1 Oncol (2004) 22:4631–4638.
  • OVERALL CM, LOPEZ-OTIN C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev Cancer (2002) 2:657–672.
  • COUISSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295:2387–2392.
  • NEW P, MIKKELSEN T, PHUPHANICH S et al: A Phase I/II study of COL-3 administered on a continuous oral schedule in patients with recurrent high-grade glioma. Preliminary results of the NABTT 9809 clinical trial. Neuro-Oncology (2002) 4:373.
  • LEVIN V, PHUPHANICH S, GLANTZ MJ et al: Randomized Phase II study of temozolomide with and without the matrix metalloprotease inhibitor prinomastat in patients with glioblastoma multiforme following best surgery and radiation therapy. Proc. Am. Soc. Clin. Oncol (2002) 21:100 (Abstract).
  • EGIDY G, EBERL LP, VALDENAIRE 0 et al.: The endothelin system in human glioblastoma. Lab. Invest. (2000) 80:1681–1689.
  • PHUPHANICH S, GROSSMAN SA, LESSER G et al.: A Phase I evaluation of the safety and pharmacokinetics of atrasentan in adults with recurrent malignant glioma: preliminary report. Neuro-Oncology (2004) 6:380 (Abstract TA–43).
  • LOVE JM, GUDAS LJ: Vitamin A, differentiation and cancer. Current Opin. Cell Biol. (1994) 6:825–831.
  • JAECKLE KA, HESS KR, YUNG WKA et al.: Phase II evaluation of temozolomide and 13- cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. ". Clin. Oncol (2003) 21:2305–2311.
  • YUNG WK, PRADOS MD, YAYA-TUR R et al.: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. I Clin. Oncol (1999) 17:2762–2771.
  • PHUPHANICH S, SCOTT C, FISCHBACH AJ et al.: All-trans-retinoic acid: A Phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. Neurooncol (1997) 34:193–200.
  • KABA SE, KYRITSIS AP, CONRAD C et al.: The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin)." Neurooncol (1997) 34:145–151.
  • DILLMAN RO, SHEA WM, TAI DF et al: Interferon-a2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro-Oncology (2001) 3:35–41.
  • PUDUVALLI VK, SAITO Y, XU R et al: Fenretinide activates caspases and induces apoptosis in gliomas. Clin. Cancer Res. (1999) 5:2230–2235.
  • PUDUVALLI VK, YUNG WKA, HESS KR et al: Phase II study of fenretinide (NSC-374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium Study. Oncol (2004) 21:4282–4289
  • BARTUS RT, ELLIOTT PJ, HAYWARD NJ et al.: Permeability of the blood-brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto regulated, receptor mediated system. Immunopharmacol (1996) 33:270–278.
  • GREGOR A, LIND M, NEWMAN H et al.: Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma." Neurooncol (1999) 44:137–145.
  • PRADOS MD, SCHOLD SC, FINE HA et al.: A randomized, double-blind, placebo-controlled, Phase II study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncology (2003) 5:96–103.
  • EMERICH DF, SNOFGRASS P, DEAN R et al: Enhanced delivery of carboplatin into brain tumors with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. BE J. Cancer (1999) 80:964–970.
  • BARTUS RT, SNOD GRASS P, MARSH J et al: Intravenous Cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. Pharmacol Exp. Ther. (2000) 293:903–911.
  • DE WIT MC, DE BRUIN HG, EIJKENBOOM W, SILLEVIS SMITT PAE, VAN DEN BENT MJ: Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology (2004) 63:535–537.
  • WOLF M, SWAISLAND H, AVERBUCH S: Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin. Cancer Res. (2004) 10:4607–4613.
  • •An intriguing proposal for a new Phase I trial methodology in the evaluation of targeted therapy.
  • BASELGA J, PFISTER D, COOPER MR et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.Oncol (2000)18:904–914.
  • PARULEKAR WR, EISENHAUER EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic Agents: theory and practice " Nat. Cancer Inst. (2004) 96:990–997.

Websites

  • http://www.eortc.be/protoc/ listprotasp?kind=sites&site=22 European Organization of Research and Treatment of Cancer website.
  • http://www.cancengov/Templates/ doc.aspx?viewid=CF77634E-36E7-47C2-A88E-9E7B163D71F3 &ReqUr1=%2fclinic altrials National Cancer Institute website.
  • http://www.mdanderson.org/care_centers/ brainspinal/dIndex.cfm?pn=09D61D62-7EA5-11D4-AEC800508BDCCE3A The University of Texas MD Anderson Cancer Center website.
  • http://www.mskcc.org/mskcc/html/ 2270.cfm?peds=no&team=Brain+Cancer& x=21&y=18. Memorial Sloan Kettering Cancer Center website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.